Onalespib is under clinical development by Astex Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Onalespib’s likelihood of approval (LoA) and phase transition for Metastatic Breast Cancer took place on 07 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Onalespib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Onalespib overview

Onalespib (AT-13387) is under development for the treatment of metastatic triple negative breast cancer, relapsed and refractory anaplastic large cell lymphoma (ALCL), mantle cell lymphoma, diffuse large B-cell lymphoma, advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, head and neck, recurrent ovarian, fallopian tube, primary peritoneal and HPV associated cancer. The drug candidate is administered intravenously. AT13387 is a second-generation, fully synthetic small molecule. It acts by inhibiting HSP90. It is developed based on Pyramid technology. It was also under development for the treatment of castration-resistant prostate cancer, HER-2 positive breast cancer, non-small cell lung cancer (NSCLC) and refractory gastrointestinal stromal tumors (GIST).

Astex Pharmaceuticals overview

Astex Pharmaceuticals is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. Astex Pharmaceuticals is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.

Quick View Onalespib LOA Data

Report Segments
  • Innovator
Drug Name
  • Onalespib
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.